Cisplatin and vinorelbine remains a valid option for the front-line chemotherapy treatment of NSCLC.

摘要

BACKGROUND: This study was designed to confirm the activity of the cisplatin/vinorelbine (C/V) combination in non-small cell lung carcinoma (NSCLC). Patients and METHODS: Treatment consisted of vinorelbine, i.v. slow infusion of 30 mg/m2 every week, and cisplatin, 120 mg/m2 on days 1 and 29 and then every 6 weeks. Treatment was continued until completion of the 22-week treatment plan, disease progression, persistent toxicity, or patient refusal. RESULTS: Seventy-five patients entered the study. The median age was 62 years; major cell types were adeno- (38), squamous (26) and large cell carcinomas (7). Nineteen patients received a suboptimal treatment with less than 6 courses of vinorelbine. The median courses of C/V were 3 (range 0-4) and 15 (range 0-22), respectively. For both drugs, the median dose-intensity was 75% of projected. Toxicity was generally acceptable, mainly hematological and never life-threatening. Thirty-five patients responded, with 8 complete responses, for an overall response rate of 46.7%. The estimated median time to progression was 28 weeks (quartile range: 13-46); the median survival 60 weeks (quartile rage: 17-108). CONCLUSION: The C/V combination is fairly well tolerated, decidedly active and associated with prolonged survivals.